Table 1 Baseline characteristics of the study population
Characteristics | Total, N = 102 (%) |
|---|---|
Age, y | |
Median | 67 |
Range | 45-83 |
Primary tumor location | |
Bladder | 84 (82.4%) |
Renal pelvis | 11 (10.8%) |
Ureter | 4 (3.9%) |
Prostatic urethra | 1 (1.0%) |
Ureter + Renal pelvis | 1 (1.0%) |
Patients comorbidities | |
Hypertension | 50.5% |
Diabetes | 20.7% |
Lipid metabolism alterations | 14.4% |
Heart medical records | 7.8% |
Lung diseases | 13.3% |
Location of distant metastasis | |
Retroperitoneal nodes | 58 (58.0%) |
Lung | 29 (29.3%) |
Bone | 20 (20.2%) |
Liver | 17 (17.2%) |
ECOG performance status when starting vinflunine | |
0 | 31 (31.3%) |
1 | 60 (60.6%) |
2 | 8 (8.1%) |
Prior platinum Regimen | |
Cisplatin | 47 (47%) |
Carboplatin | 52 (51%) |
Paclitaxel/gemcitabine | 2 (2%) |
Unknown | 1 (1%) |